Single-arm trials for domestic oncology drug approvals in China

Cancer Biol Med. 2023 Nov 27;20(11):799-805. doi: 10.20892/j.issn.2095-3941.2023.0360.

Authors

Hong Zhang^#¹, Sen Liu^#², Chenghao Ge², Xiaozhen Liu², Yang Liu², Chen Yin², Yi Li², Jing An², Zhongtian Yan², Xiaoyuan Chen^{2

3}

Affiliations

¹ Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China.
² Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
³ Office of Clinical Trial Institute, Beijing Tsinghua Changgung Hospital, Beijing 102218, China.

^# Contributed equally.

PMID: 38013490
PMCID: PMC10690876
DOI: 10.20892/j.issn.2095-3941.2023.0360

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
China
Drug Approval*
Humans
Medical Oncology

Substances

Antineoplastic Agents

Grants and funding

2023-Y-Y-002/China Society for Drug Regulation